histamine has been researched along with vonoprazan in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Arikawa, Y; Hirase, K; Hori, Y; Imanishi, A; Inatomi, N; Kajino, M; Matsukawa, J; Nishida, H; Tsukimi, Y | 1 |
| Hori, Y; Inatomi, N; Kajino, M; Matsukawa, J; Nishida, H; Takeuchi, T | 1 |
| Cha, H; Cheon, B; Cho, JH; Kim, J; Kim, JY; Kim, K; Ku, JM | 1 |
3 other study(ies) available for histamine and vonoprazan
| Article | Year |
|---|---|
1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Dithiothreitol; Gastric Acid; Gastric Mucosa; Histamine; Hydrogen-Ion Concentration; Imidazoles; In Vitro Techniques; Kinetics; Lansoprazole; Ligation; Male; Potassium; Proton Pump Inhibitors; Pylorus; Pyrroles; Rats; Rats, Sprague-Dawley; Stomach; Sulfonamides; Swine | 2010 |
A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Cimetidine; Dogs; Gastric Acid; Gastric Mucosa; H(+)-K(+)-Exchanging ATPase; Histamine; Histamine Agonists; Hydrogen-Ion Concentration; Lansoprazole; Male; Potassium; Proton Pump Inhibitors; Pyrroles; Rats; Rats, Sprague-Dawley; Sulfonamides; Time Factors | 2011 |
JP-1366: A novel and potent potassium-competitive acid blocker that is effective in the treatment of acid-related diseases.
Topics: Adenosine Triphosphatases; Animals; Gastric Acid; Gastroesophageal Reflux; Histamine; Potassium; Proton Pump Inhibitors; Quality of Life; Rats | 2023 |